Bristol Myers Squibb is deepening its collaboration with Nvidia, using the chipmaker's artificial intelligence technology to accelerate drug discovery. The expanded partnership has already delivered a 55% cost reduction on certain drug discovery workloads, the company said.
How the expanded deal works
The new phase of the partnership builds on an existing relationship. Bristol Myers Squibb will now tap Nvidia's AI platforms to run more complex simulations and analyze larger datasets. The goal is to identify promising drug candidates faster and with less trial-and-error in the lab. Nvidia's hardware and software are designed to handle the massive computational demands of molecular modeling and protein folding predictions.
The reported cost savings
Bristol Myers Squibb reported a 55% savings on drug discovery workloads after integrating Nvidia's technology. That figure comes from internal assessments comparing the cost of running the same tasks on previous systems versus the new AI-driven setup. The company did not disclose the exact dollar amount saved or the specific workloads involved, but the percentage points to significant efficiency gains.
The expanded deal covers multiple therapeutic areas, though Bristol Myers Squibb hasn't named specific diseases or drug targets. The company plans to continue rolling out Nvidia's AI tools across its research pipeline. No timeline for the next phase of the collaboration was given.
